睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06276283,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed and locally advanced or metastatic non-squamous NSCLC.

    入选标准第 3 条

  3. Post-menopausal defined as age more than 60 and amenorrheic for at least 12 months after all exogenous hormonal treatments.

    入选标准第 12 条

    Treatment with poziotinib, mobocertinib (TAK788), CLN-081, BDTX-189, aumolertinib, AP-L1898, and other EGFR Exon20ins inhibitors prior to the first dose of study drug (only applicable to Part B).

    排除标准第 2 条

    Prior treatment with 1st to 3rd generation EGFR-TKIs (e.g., gefitinib, erlotinib, icotinib, osimertinib, afatinib, dacomitinib, and ametinib) and have had an objective response (i.e., PR and CR) (only applicable to Part B).

    排除标准第 3 条

    Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy and radiotherapy) > CTCAE grade 1 at the time of starting study drug except for alopecia and grade 2 neuropathy related to previous platinum-based therapy.

    排除标准第 14 条

  4. Written documentation of EGFR mutations from an accredited local laboratory: Part A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.

    入选标准第 4 条

    Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.

    排除标准第 5 条

    Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).

    排除标准第 12 条

    Absolute neutrophil count < 1.5 × 109/L

    排除标准第 27 条

    Platelet count < 100 ×109/L

    排除标准第 28 条

    Hemoglobin < 9 g/dL

    排除标准第 29 条

    Total bilirubin >1.5 × ULN if no liver metastases or >3 × the upper limit of normal (ULN) in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases

    排除标准第 30 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST >2.5 × ULN if no demonstrable liver metastases or >5 × ULN in the presence of liver metastases.

    排除标准第 31 条

    Creatinine ≥1.5 × ULN or creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation)

    排除标准第 32 条

    The international normalized ratio > 1.5 × ULN and activated partial thromboplastin time (APTT) > 1.5 × ULN

    排除标准第 33 条

    Serum lipase) > 1.5 × ULN and serum amylase > 1.5 × ULN

    排除标准第 34 条

  5. Patients with stable brain metastasis provided no evidence of progression for at least 2 weeks, as ascertained by brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the screening period, no neurological symptoms, and no requirement of Steroids.

    入选标准第 6 条

    Measurable lesions, according to RECIST 1.1: at least one lesion, not previous irradiated, with the longest diameter ≥ 10 mm at baseline (lymph nodes must have a short axis of ≥ 15 mm), that can be accurately measured at baseline and thereafter with MRI or CT scan.

    入选标准第 9 条

  6. History of malignancy within 2 years of the first dose of study drug (excluding adequately treated Basal cell carcinoma or in situ cervical cancer with a tumor-free period of more than 2 years and a life expectancy of more than 2 years. The inclusion of such patients should be discussed with the study physician from Dizal Pharma).

    排除标准第 13 条

    Any evidence of active infection, including but not limited to hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and COVID-19. The diagnosis of COVID-19 follows the local practice.

    排除标准第 17 条

  7. Male patients with a female partner or fertility desire should be willing to use barrier contraception (e.g., condoms) until 6 months after the last dose. Male patients should not donate sperms until 6 months after the last dose. Male patients with fertility desire are suggested to freeze their sperm before entering the study.

    入选标准第 10 条

    Pregnant women or women who are breastfeeding.

    排除标准第 36 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06276283,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sufficient understanding of nature of the trial and provision of informed consent with hand-written signatures and the date of signature prior to any study-specific procedures, sampling, and analyses.
  2. Age ≥ 18 years.
  3. Histologically or cytologically confirmed and locally advanced or metastatic non-squamous NSCLC.
  4. Written documentation of EGFR mutations from an accredited local laboratory: Part A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.
  5. ECOG score ≤ 1 without clinically significant disease deterioration within 2 weeks prior to the informed consent process and a life expectancy ≥ 12 weeks.
  6. Patients with stable brain metastasis provided no evidence of progression for at least 2 weeks, as ascertained by brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the screening period, no neurological symptoms, and no requirement of Steroids.
  7. Part A includes patients who have progressed after or cannot tolerate the standard of care
  8. Part B includes patients with NSCLC who have progressed after or cannot tolerate standard of care. Treatment naïve patients will be enrolled after an adequate evaluation of the safety data by the Safety Review Committee (Note: Patients who have received (neo)adjuvant therapy are allowed to participate in the study, if the (neo)adjuvant therapy is administrated at least 6 months prior to the diagnosis of locally advanced or metastatic NSCLC) .
  9. Measurable lesions, according to RECIST 1.1: at least one lesion, not previous irradiated, with the longest diameter ≥ 10 mm at baseline (lymph nodes must have a short axis of ≥ 15 mm), that can be accurately measured at baseline and thereafter with MRI or CT scan.
  10. Male patients with a female partner or fertility desire should be willing to use barrier contraception (e.g., condoms) until 6 months after the last dose. Male patients should not donate sperms until 6 months after the last dose. Male patients with fertility desire are suggested to freeze their sperm before entering the study.
  11. Female patients should be willing to use adequate contraceptive measures, should not be breastfeeding, and must have a negative pregnancy test (i.e., urine and blood pregnancy human chorionic gonadotropin testing); or female patients meet the following criteria:
  12. Post-menopausal defined as age more than 60 and amenorrheic for at least 12 months after all exogenous hormonal treatments.
  13. Women under 60 years old would be considered post-menopausal if they have been amenorrheic for at least 12 months with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range.
  14. Documentation of irreversible surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation).

排除标准:Exclusion Criteria:

  1. Treatment with any of the following:
  2. Treatment with poziotinib, mobocertinib (TAK788), CLN-081, BDTX-189, aumolertinib, AP-L1898, and other EGFR Exon20ins inhibitors prior to the first dose of study drug (only applicable to Part B).
  3. Prior treatment with 1st to 3rd generation EGFR-TKIs (e.g., gefitinib, erlotinib, icotinib, osimertinib, afatinib, dacomitinib, and ametinib) and have had an objective response (i.e., PR and CR) (only applicable to Part B).
  4. Prior systemic treatment for locally advanced or metastatic NSCLC (only applicable to treatment naïve patients in Part B)
  5. Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.
  6. Chemotherapy or other anti-tumor therapies within 2 weeks of the first dose of study drug.
  7. Radiotherapy within 14 days of the first dose of study drug or unresolved radiotherapy-related toxicities. Patients could receive palliative radiotherapy for tumor lesions outside of brain and chest, stereotactic radiosurgery, and stereotactic body radiotherapy.
  8. Current treatment within 1-2 weeks of the first dose of study drug with medications or herbal supplements known to be potent inhibitors (1 week) or inducers (2 weeks) of cytochrome P450 (CYP) 3A4.
  9. Major surgery, excluding biopsy and diagnostic surgery, within 4 weeks of the dose of study drug, or expected major surgeries during the study period.
  10. Treatment with an investigational drug within 5 half-lives of the compound. Patient
  11. Spinal cord compression or leptomeningeal metastasis.
  12. Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
  13. History of malignancy within 2 years of the first dose of study drug (excluding adequately treated Basal cell carcinoma or in situ cervical cancer with a tumor-free period of more than 2 years and a life expectancy of more than 2 years. The inclusion of such patients should be discussed with the study physician from Dizal Pharma).
  14. Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy and radiotherapy) > CTCAE grade 1 at the time of starting study drug except for alopecia and grade 2 neuropathy related to previous platinum-based therapy.
  15. History of stroke and intracranial hemorrhage within 6 months of the first dose of study drug.
  16. Any evidence of severe or uncontrolled systematic disease based on the investigator's opinion, including uncontrolled hypertension and active bleeding diatheses (e.g., hemophilia and von Willebrand disease).
  17. Any evidence of active infection, including but not limited to hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and COVID-19. The diagnosis of COVID-19 follows the local practice.
  18. Any of the following cardiac events or abnormalities:
  19. Mean resting corrected QT interval (QTcF) > 470 msec.
  20. Any clinically significant abnormalities in rhythm, conduction, or morphology detected by resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, and PR interval > 250 msec.
  21. Any factors that can lead to QTcF prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, family history of unexplained sudden death under 40 years of age, or any comorbidities known to prolong the QT interval.
  22. Any evidence of atrial fibrillation (except for drug-related atrial fibrillation that has been resolved after drug discontinuation).
  23. Any evidence of myocadiac infraction, congestive heart failure (New York Heart Association Class II or above), and uncontrolled arrhythmia with medication within 6 months of the first dose of study drug.
  24. History of interstitial lung disease (ILD), drug-induced ILD, and immune-related pneumonitis due to cancer immunotherapy.
  25. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing the study drug, or previous bowel resection that would preclude adequate absorption of DZD9008.
  26. Inadequate bone marrow reserve or organ function:
  27. Absolute neutrophil count < 1.5 × 109/L
  28. Platelet count < 100 ×109/L
  29. Hemoglobin < 9 g/dL
  30. Total bilirubin >1.5 × ULN if no liver metastases or >3 × the upper limit of normal (ULN) in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases
  31. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST >2.5 × ULN if no demonstrable liver metastases or >5 × ULN in the presence of liver metastases.
  32. Creatinine ≥1.5 × ULN or creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation)
  33. The international normalized ratio > 1.5 × ULN and activated partial thromboplastin time (APTT) > 1.5 × ULN
  34. Serum lipase) > 1.5 × ULN and serum amylase > 1.5 × ULN
  35. Live virus vaccines administrated within 2 weeks of the first dose of study drug.
  36. Pregnant women or women who are breastfeeding.
  37. Concurrent contraindications to bevacizumab, including but not limited to:
  38. Deep vein thrombosis ≥ CTCAE grade 3
  39. Uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
  40. Intracerebral hemorrhage, including hemorrhage caused by metastatic brain tumors.
  41. History of severe proteinuria (urine dipstick protein 2+ or 24-hour urine protein > 2g)
  42. History of hypertensive crisis and hypertensive encephalopathy
  43. History of central nervous system diseases that are not related to the tumor (e.g., convulsions)
  44. History of vascular events within 6 months of the first dose of study drug (e.g., aneurysm requiring treatment)
  45. History of hemoptysis within 3 months of the first dose of study drug (two spoonfuls of blood each time)
  46. History of bleeding disorders or coagulation disorders without treatment of anticoagulants.
  47. Tumor invasion of major vessels
  48. History of gastrointestinal perforation or fistula within 6 months of the first dose of study drug
  49. Severe allergic reaction to DZD9008, bevacizumab, or their excipients.
  50. Subjects who are involved in the design, planning, or conduct of the study (applicable to employees of Dizal Pharm and staff at investigational sites).
  51. Poor compliance or inability to participate in clinical studies according to the investigator's assessment.

引自 ClinicalTrials.gov, NCT06276283, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06276283,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06276283